adc-1013
mAbexperimental
Clinical trial activity
5 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02379741)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297870 ↗
Also known as
- adc-1013
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07199764 | Phase 2 | Oct 31, 2025 | Lustgarten Foundation, University of Pennsylvania |
| NCT06205849 | Phase 1 | Jun 25, 2024 | National Cancer Institute (NCI), University of California, Los Angeles, University of California, San Diego |
| NCT04888312 | Phase 1/Phase 2 (Phase 2) | Sep 17, 2021 | 4Pharma Ltd., Alligator Bioscience AB, Free University of Brussels, Theradex |
| NCT05650918 | Phase 1 | Aug 30, 2021 | Erasmus University Rotterdam |
| NCT02379741 | Phase 1 | Apr 1, 2015 | Alligator Bioscience AB, University of Copenhagen |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alligator Bioscience AB | For profit | 2 | 2 | 2 | 2015 |
| 4Pharma Ltd. | For profit | 1 | 0 | 1 | 2021 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Free University of Brussels | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Lustgarten Foundation | Academic/Hospital | 1 | 0 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2024 |
| Theradex | For profit | 1 | 0 | 1 | 2021 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2025 |
11 organizations
Page 1 / 1